Education
About Us
Working with TipRanks
Follow Us
Novavax (NVAX)
NASDAQ:NVAX
Earnings Data
Report Date
May 07, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.43Last Year’s EPS
-1.05Same Quarter Last Year
Moderate Buy
Based on 4 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 27, 2025
|% Change Since: 3.83%
|Next Earnings Date:May 07, 2025
Earnings Call Sentiment|Neutral
The earnings call highlights several positive strategic moves by Novavax, including a significant partnership with Sanofi, financial improvements, and new pipeline initiatives. However, these are counterbalanced by challenges such as declining revenues, dependence on Sanofi for future success, and regulatory uncertainties.Company Guidance
During the Novavax Fourth Quarter 2024 Financial Results call, the company highlighted several key metrics and strategic developments. Novavax reported total revenue of $682 million for the year, with $190 million from product sales and $492 million from licensing and royalties. They successfully reduced their R&D and SG&A expenses by 40% compared to 2023, targeting further reductions in 2025. The company achieved significant milestones, including the sale of a Czech Republic manufacturing facility for $200 million, which contributed to reducing operating costs by $80 million annually. Novavax also decreased current liabilities by $1.3 billion over two years. Moving forward, the company anticipates 2025 as a transition year, focusing on a partnership with Sanofi, which includes potential milestone payments totaling $225 million and royalties in the high-teens to low 20% range. The company aims for profitability by 2027 with a breakeven revenue target of $225 million, supported by continued cost reductions and strategic partnerships.Strategic Partnership with Sanofi
Novavax announced a wide-ranging partnership agreement with Sanofi, receiving an initial cash payment of $500 million upfront and a $70 million equity investment. Sanofi will take the lead commercialization role for Novavax's COVID-19 vaccine starting this year.
Financial Improvements and Cost Reductions
Novavax reduced its current liabilities by $1.3 billion over the last two years and significantly reduced combined R&D and SG&A expenses. They are on track to decrease expenses by approximately 85% by 2027 compared to their 2022 baseline.
New Early-Stage Pipeline Initiatives
Novavax added four new early-stage assets focused on C. Diff, varicella-zoster virus, pandemic flu, and a triple RSV combination. Preclinical data from these programs are expected in the second half of the year.
Sale of Czech Republic Facility
The sale of the Czech Republic manufacturing facility for $200 million helped reduce annual operating costs by approximately $80 million.
---
NVAX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
NVAX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 27, 2025 | $7.32 | $7.06 | -3.55% |
| Nov 12, 2024 | $9.01 | $8.46 | -6.10% |
| Aug 08, 2024 | $10.71 | $11.68 | +9.06% |
| May 10, 2024 | $4.47 | $8.88 | +98.66% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Novavax (NVAX) report earnings?
Novavax (NVAX) is schdueled to report earning on May 07, 2025, TBA Not Confirmed.
What is Novavax (NVAX) earnings time?
Novavax (NVAX) earnings time is at May 07, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVAX EPS forecast?
NVAX EPS forecast for the fiscal quarter 2025 (Q1) is -0.43.
---
